Zenas BioPharma
ZBIO
28.18
+1.24
+4.60%
Zenas BioPharma
US · ZBIO
#2856 by market cap
Listed 2024
28.18
+1.24
+4.60%
Live - 5344 symbols - heartbeat 96s ago
· 2026-10-08 07:09
Pre-market
28.26
+0.28%
After-hours
28.18
0.00%
- Market cap
- 1.84B
- P/E (TTM)i
- -2.93
- P/Bi
- 7.43
- EPSi
- -8.44
- Div yieldi
- 0.00%
- 52W posi
- 47%
Reader sentiment
Are you bullish or bearish on ZBIO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 4.11, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 4 years
Latest year +100.00% YoY
Margins
- Operating margin
- -2,113.85%
- Net margin
- -3,777.37%
Key ratios & quality
- Altman Z-Scorei
- 4.11
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0 | 50.00M | 5.00M | 10.00M |
| Gross profit | -- | -- | -- | -- |
| Selling & admin expenses | 13.51M | 17.11M | 29.75M | 53.32M |
| Research & development | 61.69M | 60.03M | 139.14M | 168.06M |
| Operating profit | -75.20M | -27.15M | -163.89M | -211.39M |
| Pretax profit | -119.28M | -36.82M | -156.56M | -377.82M |
| Tax | 0 | 301.00K | 429.00K | -79.00K |
| Net profit | -119.28M | -37.12M | -156.99M | -377.74M |
| Basic EPS | -9 | -2 | -12 | -8 |
| Diluted EPS | -9.26 | -2.13 | -11.89 | -8.44 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 10.00M | 0 | 0 | 0 | 0 | 1.00M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 12.42M | 12.14M | 13.18M | 15.59M | 16.91M | 15.75M |
| Research & development | 34.92M | 43.03M | 34.40M | 55.72M | 60.44M | 62.91M |
| Operating profit | -37.33M | -55.16M | -47.58M | -71.31M | -77.35M | -77.66M |
| Pretax profit | -33.78M | -52.20M | -51.50M | -240.34M | -80.99M | -111.34M |
| Tax | -205.00K | 20.00K | 0 | 106.00K | 0 | 114.00K |
| Net profit | -33.57M | -52.22M | -51.50M | -240.44M | -80.99M | -111.46M |
| Basic EPS | -1 | -1 | -1 | -5 | -1 | -2 |
| Diluted EPS | -0.80 | -1.25 | -1.22 | -4.54 | -1.46 | -1.77 |
Balance sheet
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total current assets | 68.44M | 59.80M | 355.92M | 351.17M |
| Cash & ST investments | 67.21M | 56.86M | 350.77M | 343.19M |
| Inventory | -- | -- | -- | -- |
| Total assets | 74.58M | 68.18M | 369.97M | 383.64M |
| Total current liabilities | 25.97M | 23.26M | 57.29M | 62.65M |
| Short-term debt | 715.00K | 556.00K | 785.00K | 1.12M |
| Long-term debt | -- | 20.30M | -- | -- |
| Total liabilities | 266,865,000.00 | 293,901,000.00 | 57,510,000.00 | 141,496,000.00 |
| Total equity | -192.29M | -225.72M | 312.46M | 242.14M |
| Retained earnings | -193.28M | -230.40M | -387.39M | -765.13M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 317.81M | 278.60M | 296.64M | 351.17M | 730.16M | 653.79M |
| Cash & ST investments | 312.38M | 273.28M | 290.88M | 343.19M | 717.21M | 643.13M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 333.77M | 293.09M | 322.02M | 383.64M | 747.68M | 701.69M |
| Total current liabilities | 49.13M | 53.24M | 52.42M | 62.65M | 61.16M | 65.82M |
| Short-term debt | 908.00K | 793.00K | 618.00K | 1.12M | 1.04M | 823.00K |
| Long-term debt | -- | -- | -- | -- | 265.72M | 297.02M |
| Total liabilities | 49,449,000.00 | 53,459,000.00 | 125,590,000.00 | 141,496,000.00 | 411,853,000.00 | 454,593,000.00 |
| Total equity | 284.32M | 239.63M | 196.43M | 242.14M | 335.83M | 247.10M |
| Retained earnings | -420.96M | -473.19M | -524.69M | -765.13M | -846.12M | -957.57M |
Cash flow
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating cash flow | -65.65M | -30.53M | -119.67M | -172.33M |
| Depreciation & amortization | 78.00K | 113.00K | 137.00K | 56.00K |
| Free cash flow | -67.85M | -30.55M | -119.81M | -207.35M |
| Dividends paid | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | 0 | 240.64M | 148.57M |
| Ending cash balance | 67.30M | 56.94M | 319.83M | 110.64M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -37.05M | -41.74M | -41.13M | -52.41M | -75.20M | -57.24M |
| Depreciation & amortization | 23.00K | 12.00K | 11.00K | 10.00K | 6.00K | 4.00K |
| Free cash flow | -37.07M | -41.74M | -46.13M | -82.41M | -75.20M | -87.24M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 148.57M | 165.53M | 14.10M |
| Ending cash balance | 196.55M | 44.01M | 115.57M | 110.64M | 500.22M | 196.58M |
Returns & efficiency
| Line item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| ROE %i | -- | -- | -361.99 | -136.22 |
| ROA %i | -159.94 | -52.01 | -71.66 | -100.25 |
| ROIC %i | -- | -- | -288.44 | -137.38 |
| 5-year avg ROE %i | -- | -- | -- | -- |
| EBIT margin %i | -- | -54.29 | -3,277.76 | -3,704.89 |
| FCF / sales %i | -- | -- | -- | -- |
| Current ratioi | 2.64 | 2.57 | 6.21 | 5.61 |
| Quick ratioi | 2.59 | 2.44 | 6.12 | 5.48 |
| Debt / assetsi | 2.05 | 30.97 | 0.27 | 0.35 |
| LT debt / equityi | -- | -- | 0.07 | 0.09 |
| Interest coveragei | -- | -- | -- | -50.56 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -1,022.95 | -- | -68.33 | -136.22 | -137.11 | -199.04 |
| ROA %i | -85.03 | -71.80 | -52.35 | -100.25 | -78.63 | -97.39 |
| ROIC %i | -595.21 | -- | -68.18 | -137.38 | -95.44 | -122.00 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,157.60 | -1,260.67 | -1,304.64 | -3,704.89 | -- | -45,990.40 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.47 | 5.23 | 5.66 | 5.61 | 11.94 | 9.93 |
| Quick ratioi | 6.36 | 5.13 | 5.55 | 5.48 | 11.73 | 9.77 |
| Debt / assetsi | 0.37 | 0.34 | 0.25 | 0.35 | 35.69 | 42.45 |
| LT debt / equityi | 0.11 | 0.09 | 0.09 | 0.09 | 79.15 | 120.21 |
| Interest coveragei | -- | -- | -- | -50.56 | -29.45 | -18.96 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research and development of precision immunology-based therapies100.00%
Quote time 2026-10-08 07:09:11 · For reference only, not investment advice and not tailored to your situation.